January 25, 2023

Kick-off of the new Alzheimer's disease project in Brno

The project will generate a joint cross-border strategy covering basic and applied research activities in the field of Alzheimer’s disease diagnostics, transfer modern cutting-edge technologies into clinical practice, and accelerate the development of new diagnostics tools.

The interconnection and involvement of ecosystems - from the academic and government to business- as one of the main pillars of enhancing innovation- was highlighted by speakers and other distinguished guests who took part in the all-day-long kick-off meeting.

Stefan Weiers, a Head of Sectorat the European Commission, congratulated the Czechoslovak consortium for successful project preparation and pointed out how the pandemic worsened the innovation gap between the West and the East region.

Moreover, the ADDIT-CE project should help to design a national plan for combatting dementia in the region, since Alzheimer’s disease affects many individuals, and currently, there are no effective disease-modifying therapies.

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News